Delbridge Lea M D, Mellor Kimberley M, Taylor David J R, Gottlieb Roberta A
Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia;
Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia; Department of Physiology, University of Auckland, New Zealand; and.
Am J Physiol Heart Circ Physiol. 2015 May 15;308(10):H1194-204. doi: 10.1152/ajpheart.00002.2015. Epub 2015 Mar 6.
An understanding of the role of autophagic processes in the management of cardiac metabolic stress responses is advancing rapidly and progressing beyond a conceptualization of the autophagosome as a simple cell recycling depot. The importance of autophagy dysregulation in diabetic cardiomyopathy and in ischemic heart disease - both conditions comprising the majority of cardiac disease burden - has now become apparent. New findings have revealed that specific autophagic processes may operate in the cardiomyocyte, specialized for selective recognition and management of mitochondria and glycogen particles in addition to protein macromolecular structures. Thus mitophagy, glycophagy, and macroautophagy regulatory pathways have become the focus of intensive experimental effort, and delineating the signaling pathways involved in these processes offers potential for targeted therapeutic intervention. Chronically elevated macroautophagic activity in the diabetic myocardium is generally observed in association with structural and functional cardiomyopathy; yet there are also numerous reports of detrimental effect of autophagy suppression in diabetes. Autophagy induction has been identified as a key component of protective mechanisms that can be recruited to support the ischemic heart, but in this setting benefit may be mitigated by adverse downstream autophagic consequences. Recent report of glycophagy upregulation in diabetic cardiomyopathy opens up a novel area of investigation. Similarly, a role for glycogen management in ischemia protection through glycophagy initiation is an exciting prospect under investigation.
对自噬过程在心脏代谢应激反应管理中的作用的理解正在迅速推进,并且已超越了将自噬体视为简单细胞回收仓库的概念。自噬失调在糖尿病性心肌病和缺血性心脏病(这两种疾病构成了大部分心脏疾病负担)中的重要性现已显现。新的研究结果表明,特定的自噬过程可能在心肌细胞中发挥作用,除了蛋白质大分子结构外,还专门用于选择性识别和管理线粒体和糖原颗粒。因此,线粒体自噬、糖原自噬和巨自噬调节途径已成为深入实验研究的重点,阐明这些过程中涉及的信号通路为靶向治疗干预提供了可能性。糖尿病心肌中巨自噬活性长期升高通常与结构和功能性心肌病相关;然而,也有许多关于糖尿病中自噬抑制的有害影响的报道。自噬诱导已被确定为可用于支持缺血心脏的保护机制的关键组成部分,但在这种情况下,益处可能会因自噬的不良下游后果而减轻。最近关于糖尿病性心肌病中糖原自噬上调的报道开辟了一个新的研究领域。同样,通过启动糖原自噬在缺血保护中发挥糖原管理作用是一个正在研究的令人兴奋的前景。